Search research articles
Contact Us
Filters
Showing results (11-20 of 243) with videos related to
Page
of 25
Sort By:
Therapeutic Advances in Medical Oncology
|
January 12, 2016
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
Ivana Sullivan, David Planchard
Future Oncology (London, England)
|
October 10, 2015
AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients
Jordi Remon, David Planchard
Cancer
|
April 2, 2025
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice
Claudia Parisi, David Planchard
JTO Clinical and Research Reports
|
June 19, 2025
Erratum to 'Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796]
Mariona Riudavets, David Planchard
Therapeutic Advances in Respiratory Disease
|
October 28, 2016
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
Ivana Sullivan, David Planchard
Bulletin Du Cancer
|
November 6, 2007
[Angiogenesis targeting in lung cancers]
David Planchard, Benjamin Besse
Bulletin Du Cancer
|
November 14, 2008
[Towards customized therapy for non small cell lung cancer]
David Planchard, Benjamin Besse
Cancer Management and Research
|
February 7, 2018
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
Laura Mezquita, David Planchard
Clinical Advances in Hematology & Oncology : H&O
|
November 4, 2022
Ongoing progress in BRAF-mutated non-small cell lung cancer
Pamela Abdayem, David Planchard
European Journal of Cancer (Oxford, England : 1990)
|
September 28, 2011
Small cell lung cancer: new clinical recommendations and current status of biomarker assessment
David Planchard, Cécile Le Péchoux
Page
of 25
Search research articles
Search
Showing results (11-20 of 243) with videos related to
Sort By:
Page
of 25
Therapeutic Advances in Medical Oncology
|
January 12, 2016
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
Ivana Sullivan, David Planchard
Future Oncology (London, England)
|
October 10, 2015
AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients
Jordi Remon, David Planchard
Cancer
|
April 2, 2025
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice
Claudia Parisi, David Planchard
JTO Clinical and Research Reports
|
June 19, 2025
Erratum to 'Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796]
Mariona Riudavets, David Planchard
Therapeutic Advances in Respiratory Disease
|
October 28, 2016
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
Ivana Sullivan, David Planchard
Bulletin Du Cancer
|
November 6, 2007
[Angiogenesis targeting in lung cancers]
David Planchard, Benjamin Besse
Bulletin Du Cancer
|
November 14, 2008
[Towards customized therapy for non small cell lung cancer]
David Planchard, Benjamin Besse
Cancer Management and Research
|
February 7, 2018
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
Laura Mezquita, David Planchard
Clinical Advances in Hematology & Oncology : H&O
|
November 4, 2022
Ongoing progress in BRAF-mutated non-small cell lung cancer
Pamela Abdayem, David Planchard
European Journal of Cancer (Oxford, England : 1990)
|
September 28, 2011
Small cell lung cancer: new clinical recommendations and current status of biomarker assessment
David Planchard, Cécile Le Péchoux
Page
of 25